Therapeutic Benefit of Top-Selling Oncology Drugs in US Medicare.gov acrobat.adobe.com/id/urn:aaid:sc… via Aaron Kesselheim et al Dr Mark Lythgoe Jane Maher💙also on Bluesky

Not all PDL1 assays are the same in #bladder #cancer - important work. do we need to re-evaluate the clinical utility of how we measure PDL1 and does this have implications for other cancers??? David J. Benjamin, MD Tom Powles Dr Amol Akhade Fight Bladder Cancer aacrjournals.org/cancerimmunolr…

Great to see #subcutaneous #nivolumab approved in the #UK to enhance patient experience and access in lung, melanoma, kidney and many other cancer types Cancer Research UK Melanoma Focus UK Roy Castle Lung Cancer Foundation BTOG Sanjay Popat Tom Powles Kidney Cancer UK gov.uk/government/new…

Do we need to rationalise CT Scan in #medicine? . Study in JAMA Internal Medicine suggests current CT usage could result in 1 in 20 of ALL cancers in the near-future.......... jamanetwork.com/journals/jamai… Ash Paul Richard Sullivan Dr Amol Akhade OncoDaily Bishal Gyawali, MD, PhD, FASCO OncoAlert Oncology Brothers

Brand new paper just live in BMJ Oncology . In this study, we evaluate if DFS can be a reliable surrogate for OS in early-stage pancreatic cancer trials. I hope trial sponsors and trialists will find these results helpful and meaningful. Link in next comment. Special shout out to

Several malignancies for which there are no medicines recommended on the EML, including stomach, liver, esophagus, thyroid, bladder, pancreas, kidney, uteri, gallbladder, vulva, penis, mesothelioma, and vaginal cancers (30% of cancer cases globally) academic.oup.com/jnci/article/d…

Reading and Interpreting Quality-of-Life Results in Cancer Trials evidence.nejm.org/doi/full/10.10… via Massimo Di Maio Jane Maher💙also on Bluesky Dr Mark Lythgoe

An incredible dr #Leone Università degli Studi di Milano presenting on patterns of inclusion & persisting barriers for access in clinical trials 4 patients wt #cancer & #HIV #PLWH Filippo Pietrantonio #ASCO25 ASCO AIOM

Honoured to be inducted as a fellow of the American Society of Clinical Oncology at the opening ceremony yesterday. Thank you ASCO .

Outstanding work by Chris Booth and colleagues - major impact - and showing just what non pharmaceutical interventions can actually achieve!! World Health Organization (WHO) ASCO ESMO - Eur. Oncology

💡New in JCP with Ariadna Tibau Martorell Aaron Kesselheim We find the time for U.S. FDA oncology indications to achieve conversion to regular approval or be withdrawn has shortened. Also, prop of confirmatory studies underway at the time of approval has increased. sciencedirect.com/science/articl…

Excellent article 'The Catch in Catching Cancer Early' from Siddhartha Mukherjee in the The New Yorker discussing the promise of #early #cancer #detection and the experience with #GRAIL in NHS Richard Sullivan Bishal Gyawali, MD, PhD, FASCO Ash Paul Eric Topol Sarah Blagden newyorker.com/magazine/2025/….

Dr Mark Lythgoe Siddhartha Mukherjee The New Yorker NHS Richard Sullivan Bishal Gyawali, MD, PhD, FASCO Eric Topol Sarah Blagden Yup, already tweeted that excellent Siddhartha Mukherjee article in The New Yorker earlier this morning NHS England Naser Turabi Paul Pharoah (R soul) 🇪🇺🇵🇬🇿🇦🇬🇧

Thank you Cancer Today AACR for featuring our recent ESMO - Eur. Oncology Real World Data & Digital Oncology study on the portrayal of cancer in public figures in news stories. The public should be cognizant that many news articles lack pertinent details on an individual's diagnosis,

Simple things work best in #clinical #trial recruitment - single page recruitment letter………….though no preference in different colours! Ash Paul ECMC Network (@ecmc-uk.bsky.social) Sarah Blagden jamanetwork.com/journals/jama/…

🚨Our RWE #perioperative #NSCLC study now in JAMA Network Open study of 1334 pts with stage II–IIIA resectable NSCLC: ◼️Neoadj DMFS @ 18 mo: 80% ◼️Adj DMFS @ 18 mo: 83 % ◼️Uptake was low: <30% ◼️Favorable outcomes, but time to expand access OncoAlert bit.ly/3I5Aeck

Massive congratulations our fantastic Clinical Research Fellow Dr James Clark on passing his PhD viva this afternoon!!! 🎉🎉🎉 Huge thank you to his lovely examiners Professors Gourley and Aboagye for an excellent discussion! Surgery and Cancer Imperial College London

>100000 single-arm trials exist. Most use convenience samples & give weak non-generalizable evidence. We can do better. We propose Random Invitation Single-Arm Trials (RISAT) - a simple way to get randomized real-world evidence from SATs. Annals of Int Med acpjournals.org/doi/10.7326/AN…

#UK healthcare research is in serious decline in latest @nature rankings No institution in top 50 #globally or even top 25 in #Europe………….links to decline of #physican #Scientists nature.com/nature-index/r… Cancer Research UK Policy UK Research and Innovation Richard Sullivan The BMJ Andrew Gregory

Exciting to see the trial I wrote at ASCO AACR #VailWorkshop2019 published. Thanks to mentor Petros Grivas and for the team Fred Hutch Cancer Center carrying this through to completion! #PDG6